LEADER 05014nam 22006735 450 001 9910377840203321 005 20200703003736.0 010 $a3-030-28400-X 024 7 $a10.1007/978-3-030-28400-8 035 $a(CKB)4100000010236924 035 $a(DE-He213)978-3-030-28400-8 035 $a(MiAaPQ)EBC6038297 035 $a(PPN)242976603 035 $a(EXLCZ)994100000010236924 100 $a20200207d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHCV: The Journey from Discovery to a Cure $eVolume II /$fedited by Michael J. Sofia 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (VIII, 500 p. 50 illus., 20 illus. in color.) 225 1 $aTopics in Medicinal Chemistry,$x1862-2461 ;$v32 311 $a3-030-28399-2 327 $aNS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen HarvoniŽ -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens EpclusaŽ and VoseviŽ -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, HarvoniŽ) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, EpclusaŽ) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, VoseviŽ) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIERŽ -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure. 330 $aHepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I". 410 0$aTopics in Medicinal Chemistry,$x1862-2461 ;$v32 606 $aMedicinal chemistry 606 $aVirology 606 $aMedical biochemistry 606 $aBioorganic chemistry 606 $aPharmaceutical technology 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aVirology$3https://scigraph.springernature.com/ontologies/product-market-codes/B22003 606 $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005 606 $aBioorganic Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C19010 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 615 0$aMedicinal chemistry. 615 0$aVirology. 615 0$aMedical biochemistry. 615 0$aBioorganic chemistry. 615 0$aPharmaceutical technology. 615 14$aMedicinal Chemistry. 615 24$aVirology. 615 24$aMedical Biochemistry. 615 24$aBioorganic Chemistry. 615 24$aPharmaceutical Sciences/Technology. 676 $a616.362306 676 $a616.3623 702 $aSofia$b Michael J$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910377840203321 996 $aHCV: The Journey from Discovery to a Cure$91732378 997 $aUNINA